Among once-weekly GLP-1 receptor agonists, semaglutide was superior to dulaglutide and exenatide for HbA1c reduction and weight loss, with all three offering cardiovascular and potential kidney benefits.
Semaglutide superior head-to-headSuperior to both dulaglutide and exenatide ER for HbA1c reduction and weight loss in direct comparison trials
What the researchers found
Semaglutide subcutaneous was superior to dulaglutide and exenatide ER for HbA1c and weight reduction in head-to-head trials, with both semaglutide and dulaglutide showing cardiovascular and renal benefits.
Why it matters
Clinicians need to choose between GLP-1 drugs for their patients. This comprehensive comparison helps match the right drug to the right patient based on glycemic, weight, and cardiovascular priorities.
The numbers in context
31 trials; semaglutide superior to dulaglutide and exenatide ER for HbA1c and weight; CV benefits for semaglutide and dulaglutide
How the study worked
Narrative review of 31 Phase 3 clinical trials from dulaglutide, exenatide ER, and semaglutide clinical development programs, comparing glycemic, weight, cardiovascular, and renal outcomes.
Who was studied
Adults with type 2 diabetes across treatment spectrum (treatment-naive to insulin users)
What this study cannot tell us
Narrative review — not a formal meta-analysis; cross-trial comparisons have limitations; exenatide ER data less comprehensive than semaglutide; head-to-head vs. daily GLP-1 RAs had mixed results.
How to read the evidence
Based on 31 Phase 3 randomized trials including head-to-head comparisons and cardiovascular outcome trials — strong clinical evidence base.
When this study was published
Published in 2020; the GLP-1 landscape has since expanded with oral semaglutide, higher-dose semaglutide, and tirzepatide.
The bigger picture
This review captures the moment when GLP-1 RAs transitioned from glucose-lowering drugs to multi-benefit therapies addressing diabetes, obesity, cardiovascular disease, and kidney protection simultaneously.
Questions still open
- Does semaglutide superiority justify its higher cost over dulaglutide?
- How do oral semaglutide results compare to the subcutaneous formulation?
- Will tirzepatide (dual GIP/GLP-1) outperform all single-target GLP-1 RAs?
Common questions
Which once-weekly GLP-1 drug is best for diabetes?
Are weekly GLP-1 shots better than insulin?
Read the original research
Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 28-42
Citation
Patel, Dhiren. (2020). Glycaemic and non-glycaemic efficacy of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.. Journal of clinical pharmacy and therapeutics, 45 Suppl 1(Suppl 1), 28-42. https://doi.org/10.1111/jcpt.13224